Sanofi (NASDAQ:SNY) Releases Quarterly Earnings Results, Beats Expectations By $1.35 EPS

Sanofi (NASDAQ:SNY - Get Free Report) released its quarterly earnings results on Friday. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35, Zacks reports. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. During the same period in the prior year, the firm earned $2.55 EPS. The company's revenue was up 12.3% compared to the same quarter last year.

Sanofi Trading Up 0.0 %

SNY traded up $0.02 on Monday, hitting $54.36. The company had a trading volume of 3,461,899 shares, compared to its average volume of 2,039,946. The company has a market cap of $137.96 billion, a PE ratio of 27.73, a PEG ratio of 1.55 and a beta of 0.60. Sanofi has a 12-month low of $44.05 and a 12-month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business's fifty day simple moving average is $56.08 and its 200 day simple moving average is $51.78.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on SNY shares. Citigroup raised Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. Argus raised their price target on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a report on Friday, July 26th. Finally, StockNews.com cut Sanofi from a "strong-buy" rating to a "buy" rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.